Jubilant Biosys and Mnemosyne Pharmaceutical have entered a drug discovery collaboration to identify preclinical candidates for neuropsychiatric diseases from Mnemosyne’s subunit selective NMDA receptor modulators (SNRMs).
 
Mnemosyne will apply its NMDA receptor pharmacology expertise, supported by Jubilant’s translational center in Malvern, PA and facilities based in India. The collaboration will leverage capabilities across medicinal chemistry, NMDA receptor pharmacology, electrophysiology, computational chemistry and DMPK and in vivo pharmacology. Mnemosyne will own all IP generated and will be responsible for clinical development and commercialization.
 
Sri Mosur, chief executive officer and president of Global Drug Discovery & Development at Jubilant, said, “We are pleased to collaborate with Mnemosyne Pharmaceuticals on the SNRM platform. We are excited about the Mnemosyne programs and enthused that our ion channel expertise in Malvern, PA supported by capabilities in India will be leveraged in this collaboration to deliver optimal outcomes in the difficult area of neuroscience research.”
 
Mnemosyne’s chief executive officer, Dr. Kollol Pal, said, “Mnemosyne is very impressed with the integrated chemistry and biology expertise that has been assembled by Jubilant, particularly in the area of ion channels and neuroscience.  We are looking forward to a successful collaboration with Jubilant that will produce first-in-class drugs that address the unmet medical need in neuropsychiatric diseases such as schizophrenia and Alzheimer’s disease.”